A novel GSK-3β inhibitor YQ138 prevents neuronal injury induced by glutamate and brain ischemia through activation of the Nrf2 signaling pathway

Acta Pharmacologica Sinica

Volumn 37, Issue 6, 2016, Pages 741-752

  Pang, Tao ^a   Wang, Yun Jie ^a   Gao, Yuan Xue ^a   Xu, Yuan ^a   Li, Qiu ^b   Zhou, Yu Bo ^c   Xu, Lei ^c   Huang, Zhang Jian ^a   Liao, Hong ^a   Zhang, Lu Yong ^a   Gao, Jian Rong ^b   Ye, Qing ^b   Li, Jia ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

brain ischemia; cerebellar granule cells; glutamate excitotoxicity; GSK 3 inhibitor; middle cerebral artery occlusion; neuroprotection; Nrf2; OGD; YQ138

Indexed keywords

BETA CATENIN; GLUTAMIC ACID; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; HEME OXYGENASE 1; NEUROPROTECTIVE AGENT; NQO1 PROTEIN; PROTEIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TAU PROTEIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; YQ 138; GSK3B PROTEIN, RAT; NFE2L2 PROTEIN, RAT; PROTEIN KINASE INHIBITOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN ISCHEMIA; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; FEMALE; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; MALE; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; METABOLISM; MOLECULAR DOCKING; NERVE CELL; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CELLS, CULTURED; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3 BETA; MALE; MOLECULAR DOCKING SIMULATION; NEURONS; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84973340609     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2016.3     Document Type: Article

References (38)

1. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262: 689-95.
2. Chamoun R, Suki D, Gopinath SP, Goodman JC, Robertson C. Role of extracellular glutamate measured by cerebral microdialysis in severe traumatic brain injury. J Neurosurg 2010; 113: 564-70.
3. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 2010; 460: 525-42.
4. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371: 1612-23.
5. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990; 9: 2431-8.
6. Wang J, Pang T, Hafko R, Benicky J, Sanchez-Lemus E, Saavedra JM. Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARγ activation. Neuropharmacology 2014; 79: 249-61.
7. Leroy K, Brion JP. Developmental expression and localization of glycogen synthase kinase-3beta in rat brain. J Chem Neuroanat 1999; 16: 279-93.
8. Seira O, Del Rio JA. Glycogen synthase kinase 3 beta (GSK3β) at the tip of neuronal development and regeneration. Mol Neurobiol 2014; 49: 931-44.
9. Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 1994; 4: 1077-86.
10. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 2001; 20: 27-39.
11. Castro A, Martinez A. A new therapeutical strategy for the treatment of Alzheimer's disease and other neurodegenerative disorders. Expert Opin Ther Pat 2000; 10: 1519-8.
12. Cross DAE, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurons from death. J Neurochem 2001; 77: 94-102.
13. Bhat RV, Shanley J, Correll MP, Fieles WE, Keith RA, Scott CW, et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci U S A 2000; 97: 11074-9.
14. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998; 9: 2081-4.
15. Leng Y, Chuang DM. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 2006; 26: 7502-12.
16. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 2008; 28: 2576-88.
17. Cuadrado A. Structural and functional characterization of NRF2 degradation by glycogen synthase kinase 3/β-TrCP. Free Radic Biol Med 2015; 88: 147-57.
18. Satoh T, McKercher SR, Lipton SA. Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. Free Radic Biol Med 2013; 65: 645-57.
19. Chen J. Heme oxygenase in neuroprotection: from mechanisms to therapeutic implications. Rev Neurosci 2014; 25: 269-80.
20. Pang T, Sun LX, Wang T, Jiang ZZ, Liao H, Zhang LY. Telmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPARγ and the Akt/GSK-3β pathway. Acta Pharmacol Sin 2014; 35: 727-37.
21. Liu F, Wang Y, Yan M, Zhang L, Pang T, Liao H. Glimepiride attenuates Aβ production via suppressing BACE1 activity in cortical neurons. Neurosci Lett 2013; 557: 90-4.
22. Chen T, Wang J, Li C, Zhang W, Zhang L, An L, et al. Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition. Sci Rep 2014; 4: 5531.
23. Gao Y, Xu X, Chang S, Wang Y, Xu Y, Ran S, et al. Totarol prevents neuronal injury in vitro and ameliorates brain ischemic stroke: Potential roles of Akt activation and HO-1 induction. Toxicol Appl Pharmacol 2015; 289: 142-54.
24. Hetman M, Cavanaugh JE, Kimelman D, Xia Z. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci 2000; 20: 2567-74.
25. Gunasekar PG, Kanthasamy AG, Borowitz JL, Isom GE. NMDA receptor activation produces concurrent generation of nitric oxide and reactive oxygen species: implication for cell death. J Neurochem 1995; 65: 2016-21.
26. Savolainen KM, Loikkanen J, Eerikainen S, Naarala J. Glutamate-stimulated ROS production in neuronal cultures: interactions with lead and the cholinergic system. Neurotoxicology 1998; 19: 669-74.
27. Zhang Q, Ding M, Cao Z, Zhang J, Ding F, Ke K. Pyrroloquinoline quinine protects rat brain cortex against acute glutamate-induced neurotoxicity. Neurochem Res 2013; 38: 1661-71.
28. Yang YC, Lii CK, Lin AH, Yeh YW, Yao HT, Li CC, et al. Induction of glutathione synthesis and heme oxygenase 1 by the flavonoids butein and phloretin is mediated through the ERK/Nrf2 pathway and protects against oxidative stress. Free Radic Biol Med 2011; 51: 2073-81.
29. Valdivia A, Perez-Alvarez S, Aroca-Aguilar JD, Ikuta I, Jordan J. Superoxide dismutases: a physiopharmacological update. J Physiol Biochem 2009; 65: 195-208.
30. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000; 275: 16023-9.
31. Rojo AI, Sagarra MR, Cuadrado A. GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J Neurochem 2008a; 105: 192-202.
32. Rojo AI, Rada P, Egea J, Rosa AO, López MG, Cuadrado A. Functional interference between glycogen synthase kinase-3 beta and the transcription afctor Nrf2 in protection against kainite-induced hippocampal cell death. Mol Cell Neurosci 2008; 39: 125-32.
33. Budni J, Lobato KR, Binfaré RW, Freitas AE, Costa AP, Martín-de-Saavedra MD, et al. Involvement of PI3K, GSK-3β and PPARγ in the antidepressant-like effect of folic acid in the forced swimming test in mice. J Psychopharmacol 2012; 26: 714-23.
34. Zhu LQ, Wang SH, Liu D, Yin YY, Tian Q, Wang XC, et al. Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J Neurosci 2007; 27: 12211-20.
35. Lim JC, Kania KD, Wijesuriya H, Chawla S, Sethi JK, Pulaski L, et al. Activation of beta-catenin signalling by GSK-3 inhibition increases pglycoprotein expression in brain endothelial cells. J Neurochem 2008; 106: 1855-65.
36. Castellanos M, Sobrino T, Pedraza S, Moldes O, Pumar JM, Silva Y, et al. High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology 2008; 71: 1862-8.
37. Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 1996; 2: 783-7.
38. Wu J, Ling J, Wang X, Li T, Liu J, Lai Y, et al. Discovery of a potential anti-ischemic stroke agent: 3-pentylbenzo[c]thiophen-1(3H)-one. J Med Chem 2012; 55: 7173-81.